Cardiovascular effects of 6 months of hormone replacement therapy versus placebo: Differences associated with years since menopause

American Journal of Obstetrics and Gynecology

Volumn 190, Issue 4, 2004, Pages 1052-1058

  Brownley, Kimberly A ^a   Hinderliter, Alan L ^a   West, Sheila G ^b   Grewen, Karen M ^a   Steege, John F ^a   Girdler, Susan S ^a   Light, Kathleen C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Blood pressure; Hormone replacement therapy; Menopause; Stress

Indexed keywords

CATECHOLAMINE; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; NORADRENALIN; PLACEBO; PROGESTERONE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DECISION MAKING; EVALUATION; FEMALE; HEALTH; HEMODYNAMICS; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; NEUROENDOCRINE SYSTEM; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; STRESS; SYMPATHETIC TONE; TIME; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 1842477384     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2003.09.045     Document Type: Article

References (23)

1. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
2. Folsom AR, Mink PJ, Seller TA, Hong CP, Zheng W, Potter JD. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health 1995;85:1128-32.
3. Ettinger B, Friedman GD, Bush T, Quesenberry CP Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996;87:6-12.
4. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75.
5. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
6. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Synder TE, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9.
7. Girdler SS, Hinderliter AL, West SG, Grewen K, Steege J, Light KC. Postmenopausal smokers show reduced hemodynamic benefit from oral hormone replacement. Am J Cardiol 2000;86:590-2.
8. West SG, Hinderliter AL, Wells EC, Girdler SS, Light KC. Transdermal estrogen reduces vascular resistance and serum cholesterol in postmenopausal women. Am J Obstet Gynecol 2001;184:926-33.
9. Meyer WR, Costello N, Straneva P, West SG, Copeland K, Girdler SS. The effect of low dose estrogen on hemodynamic response to stress. Fertil Steril 2001;75:394-9.
10. Eaker Ed, Castelli WP. Coronary heart disease and its risk factors among women in the Framingham Study. In: Eaker E, Packard B, Wenger NK, Clarkson TB, Tyroler HA, editors. Coronary heart disease in women. New York: Haymarket Doyma; 1987. p. 122-32.
11. Aygen EM, Karakucuk EI, Basbug M. Comparison of the effects of conjugated estrogen treatment on blood lipid and lipoprotein levels when initiated in the first or fifth postmenopausal year. Gynecol Endocrinol 1999;13:118-22.
12. Hadjidakis D, Kokkinakis E, Sfakianakis M, Raptis SA. The type and time of menopause as decisive factors for bone mass changes. Eur J Clin Invest 1999;29:877-85.
13. Light KC, Hinderliter AL, West SG, Grewen KM, Steege J, Sherwood A, et al. Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women. J Hypertens 2001;19:269-78.
14. Sherwood A, May C, Siegel W, Blumenthal JA. Ethnic differences in hemodynamic responses to stress in hypertensive men and women. Am J Hypertens 1995;8:552-7.
15. van Ittersum FJ, van Baal WM, Kenemans P, Mijatovic V, Donker AJ, van der Mooren MJ, et al. Ambulatory - not office - blood pressures decline during hormone replacement therapy in healthy postmenopausal women. Am J Hypertens 1998;11:1147-52.
16. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
17. Herrington DM, Howard TD, Hawkins GA, Reboussin DM, Xu J, Zheng SL, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002;346:967-74.
18. Wang Q, Hassager C, Ravn P, Wang S, Christiansen C. Total and regional body composition changes in early postmenopausal women: age-related or menopause related? Am J Clin Nutr 1994;60:843-8.
19. Trevisan C, Ortolani S, Bianchi ML, Caraceni MP, Ulivieri FM, Gandolini G, et al. Age, time since menopause, and body parameters as determinants of female spinal bone mass: a mathematical model. Calcif Tissue Int 1991;49:1-5.
20. Christiansen C. What should be done at the time of menopause? Am J Med 1995;98(Suppl 2A):56-9.
21. Gibbs RB. Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats. Neurobiol Aging 2000;21:107-16.
22. Scuteri A, Bos AJG, Brant LJ, Talbot L, Ladatta EG, Fleg JL. Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann Intern Med 2001;135:229-38.
23. Herrington DM, Espeland MA, Crouse JR, Robertson J, Riley WA, McBurnie MA, et al. Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler Thromb Vasc Biol 2001;21:1955-61.